An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1

BACKGROUND: The long-term efficacy and safety of the 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) and 3-drug single-tablet regimens recommended for antiretroviral therapy (ART)-naive people with HIV-1 (PWH) have yet to be compared directly in clinical trials. This indirect treatment comparis...

Descripción completa

Detalles Bibliográficos
Autores principales: Evitt, Lee A., Nanji, Sakina, Grove, Richard A., Okoli, Chinyere, van Wyk, Jean, Snedecor, Sonya J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031916/
https://www.ncbi.nlm.nih.gov/pubmed/36949442
http://dx.doi.org/10.1186/s12981-023-00507-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031916/
https://www.ncbi.nlm.nih.gov/pubmed/36949442
http://dx.doi.org/10.1186/s12981-023-00507-1

Ejemplares similares